article thumbnail

Curzon Sponsors the 2024 AMBS Case Interview Competition

Curzon Consulting

17th October 2024 2 Minutes Curzon Consulting is thrilled to sponsor this year’s Alliance Manchester Business School Consultancy Case Competition. Introduced in 2016, the competition enables AMBS MBA students to showcase their skills, innovative thinking, and problem-solving abilities.

article thumbnail

Enhancing competitiveness of European life sciences

European Pharmaceutical Review

Conclusions from the meeting of the special European Council (17-18 April 2024) have recognised a need for new European competitiveness deal “anchored in a fully integrated Single Market”. The post Enhancing competitiveness of European life sciences appeared first on European Pharmaceutical Review.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Securing Europe’s competitiveness in life sciences

European Pharmaceutical Review

Nathalie Moll, Director General, the European Federation of Pharmaceutical Industries and Associations (EFPIA), has commended inclusion of a “dedicated life sciences strategy” in the Political Guidelines for the Next European Commission 2024-2029. As such, she noted that the initial priority will be “prosperity and competitiveness.”

article thumbnail

Indivior slashes revenue projection and headcount, drops schizophrenia med

Fierce Pharma

Indivior has slashed its projected revenue increase for 2024 from 18% to 8%, citing competitive pressure for top-selling product Sublocade.

article thumbnail

How health plans can leverage competitive intelligence data today to drive impact in 2024

Clarify Health

The strategic use of competitive intelligence data is increasingly becoming a crucial factor for healthcare payers looking to make informed decisions around strategic market expansion and strengthen their market position.

article thumbnail

Promising schizophrenia drug faces tough competition

European Pharmaceutical Review

GlobalData’s report showed LY03010 is expected to launch in the US in 2024. Should LY03010 receive US Food and Drug Administration (FDA) approval, Luye Pharma will need to provide solid marketing and competitive pricing to set it apart from competitors and convince payers to reimburse it.”. million in 2031, representing 0.6

article thumbnail

Financial factors to support and challenge Pharma in 2024

European Pharmaceutical Review

According to results from a survey by GlobalData, the top challenges for the pharmaceutical industry in 2024 will be inflation, geopolitical conflict and drug pricing pressures. Data outcomes revealed that most respondents from Pharma considered that drug pricing and reimbursement constraints will have a negative impact in 2024.

Pharma 102